UNITED STATES
                SECURITIES AND EXCHANGE COMMISSION
                      Washington, D.C. 20549

                            FORM 10-QSB

(Mark One)
[X]             QUARTERLY REPORT PURSUANT TO SECTION 13
                OR 15(d) OF THE SECURITIES EXCHANGE ACT
                OF 1934

For the quarterly period ended: February 29, 2004

Or
[  ]            TRANSITION REPORT PURSUANT TO SECTION 13
                OR 15(d) OF THE SECURITIES EXCHANGE ACT
                OF 1934

For the transition period from ____________ to _____________

Commission File Number: 000-31431


                       US BIODEFENSE, INC.
                 --------------------------------
     (Exact name of registrant as specified in its charter)


           Utah                             33-0052057
       -----------------               --------------------
(State or other jurisdiction of  (I.R.S. Employer Identification
incorporation or organization)                 No.)


     13674 E. Valley Blvd.                    91746
     City of Industry, CA                    -------
  ---------------------------              (Zip Code)
(Address of principal executive
           offices)

                         (626) 961-8039
                      ----------------------
      (Registrant's telephone number, including area code)

                               N/A
                           -----------
 (Former name, former address and former fiscal year, if changed
                       since last report)

  Indicate by check mark whether the registrant (1) has filed all
    reports required to be filed by Section 13 or 15(d) of the
Securities Exchange Act of 1934 during the preceding 12 months (or
 for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
                       for the past 90 days.
                          Yes [X] No [ ]

   APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS
                 DURING THE PRECEDING FIVE YEARS:
    Indicate by check mark whether the registrant has filed all
 documents and reports required to be filed by Sections 12, 13 or
  15(d) of the Securities Exchange Act of 1934 subsequent to the
   distribution of securities under a plan confirmed by a court.
                          Yes [ ] No [ ]

               APPLICABLE ONLY TO CORPORATE ISSUERS:
 Indicate the number of shares outstanding of each of the issuer's
    classes of common stock, as of the latest practicable date:
                            10,101,349





                                -1-







                        US Biodefense, Inc.



                         Table of Contents
                                                                    Page
PART I - FINANCIAL INFORMATION

  Item 1. Financial Statements                                       3

     Balance Sheet                                                   4

     Statements of Operations                                        5

     Statements of Cash Flows                                        6

     Notes                                                           7

  Item 2. Management's Discussion and Plan of Operation              9

PART II - OTHER INFORMATION

  Item 4. Controls and Procedures                                   11

  Item 6. Exhibits                                                  11

SIGNATURES                                                          12

CERTIFICATION                                                       12




















                                -2-





                  PART I - FINANCIAL INFORMATION
              Item 1. Unaudited Financial Statements

     The  accompanying unaudited financial  statements  have   been
prepared   in   accordance   with   generally  accepted  accounting
principles  for  interim financial reporting and  pursuant  to  the
rules  and  regulations of the Securities and  Exchange  Commission
("Commission").    While  these  statements  reflect   all   normal
recurring  adjustments  which are, in the  opinion  of  management,
necessary  for  fair  presentation of the results  of  the  interim
period,  they  do not include all of the information and  footnotes
required  by generally accepted accounting principles for  complete
financial  statements.   For  further  information,  refer  to  the
financial  statements and footnotes thereto, which are included  in
the  Company's  Registration Statement on  Form  10-KSB  previously
filed  with  the  Commission  on March  16,  2004,  and  subsequent
amendments made thereto.

     The   accompanying  notes  are  an  integral  part  of   these
financial statements.


































                                -3-





                        US Biodefense, Inc.
                           Balance Sheet
                            (unaudited)

                                                          February 29,
                                                              2004
Assets                                                   --------------

Current assets:
  Cash                                                           $-
  Prepaid services - related party                           10,000
  Prepaid services                                           12,000
                                                         --------------
    Total current assets                                     22,000
                                                         --------------

                                                            $22,000
                                                         ==============
Liabilities and Stockholders' Equity

Current liabilities:
  Accounts payable                                              $99
  Notes payable - related party                               3,500
                                                         --------------
    Total current liabilities                                 3,599
                                                         --------------
Stockholders' equity:
  Common stock, $0.001 par value, 100,000,000 shares
    authorized, 10,101,349 shares issued and outstanding     10,101
Additional paid-in capital                                3,793,289
Accumulated deficit                                      (3,784,989)
                                                         --------------
                                                             18,401
                                                         --------------

                                                            $22,000
                                                         ==============



  The accompanying notes are an integral part of these financial
                            statements.





                                -4-





                        US Biodefense, Inc.
                     Statements of Operations
                            (unaudited)

                                                          Three Months Ended
                                                             February 29,
                                                          2004          2003
                                                        ----------------------

Revenue                                                       $-          $-
                                                        ----------------------
Expenses:
  General and administrative expenses                      3,599           -
  General and administrative expenses - related party     15,000           -
                                                        ----------------------
Total expenses                                            18,599           -
                                                        ----------------------

Net (loss)                                              $(18,599)         $-
                                                        ======================
Weighted average number of
common shares outstanding - basic and fully diluted   10,101,349     101,349
                                                        ======================
Net (loss) per share - basic & fully diluted              $(0.00)         $-
                                                        ======================






  The accompanying notes are an integral part of these financial
                            statements.














                                -5-





                        US Biodefense, Inc.
                     Statements of Cash Flows
                            (unaudited)

                                                  Three Months Ended
                                                     February 29,
                                                   2004         2003
                                               ------------------------
Cash flows from operating activities
  Net (loss)                                    $(18,599)         $-
  Adjustment to reconcile net (loss) to
   net cash (used) by operating activities:
    Decrease in prepaid expense                   15,000           -
    Increase in accounts payable                      99           -
                                               ------------------------
Net cash (used) by operating activities           (3,500)          -
                                               ------------------------

Cash flows from financing activities
  Proceeds from notes payable - related party      3,500           -
  Issuances of common stock                            -           -
                                               ------------------------
Net cash provided by financing activities          3,500           -
                                               ------------------------

Net increase (decrease) in cash                        -           -
Cash - beginning                                       -           -
                                               ------------------------
Cash - ending                                         $-          $-
                                               ========================
Supplemental information:
  Interest paid                                       $-          $-
                                               ========================
  Income taxes paid                                   $-          $-
                                               ========================




  The accompanying notes are an integral part of these financial
                            statements.





                                -6-





                        US Biodefense, Inc.
                               Notes

Note 1 - Basis of presentation

The  interim  financial statements included  herein,  presented  in
accordance   with  United  States  generally  accepted   accounting
principles  and  stated in US dollars, have been  prepared  by  the
Company,  without audit, pursuant to the rules and  regulations  of
the  Securities  and Exchange Commission.  Certain information  and
footnote  disclosures  normally included  in  financial  statements
prepared   in   accordance  with  generally   accepted   accounting
principles  have been condensed or omitted pursuant to  such  rules
and regulations, although the Company believes that the disclosures
are adequate to make the information presented not misleading.

These  statements  reflect all adjustments,  consisting  of  normal
recurring  adjustments, which, in the opinion  of  management,  are
necessary  for  fair  presentation  of  the  information  contained
therein.   It is suggested that these interim financial  statements
be read in conjunction with the financial statements of the Company
for the year ended November 30, 2003 and notes thereto included  in
the Company's Form 10-KSB.  The Company follows the same accounting
policies in the preparation of interim reports.

Results of operations for the interim periods are not indicative of
annual results.

Note 2 - Going concern

The  accompanying financial statements have been prepared  assuming
the  Company  will continue as a going concern.  As  shown  in  the
accompanying financial statements, the Company has incurred  a  net
loss  of $18,599 for the three months ended February 29, 2004,  and
had  no  sales.   The future of the Company is dependent  upon  its
ability  to  obtain financing and upon future profitable operations
from  the development of its new business opportunities.  In  order
to  obtain  the  necessary capital, the Company is  seeking  equity
and/or   debt  financing.   If  the  financing  does  not   provide
sufficient  capital, some of the shareholders of the  Company  have
agreed  to provide sufficient funds as a loan over the next  twelve
month  period.   The  financial  statements  do  not  include   any
adjustments  relating to the recoverability and  classification  of
recorded   assets,   or  the  amounts  of  and  classification   of
liabilities that might be necessary in the event the Company cannot
continue in existence.
These  conditions  raise  substantial  doubt  about  the  Company's
ability to continue as a going concern.  These financial statements
do   not  include  any  adjustments  that  might  arise  from  this
uncertainty.

Note 3 - Prepaid expense

On  April 1, 2003, the Company entered into an employment agreement
with  an  individual who is an officer and director of the company.
The  compensation  is  $60,000 annually.   The  Company  recognized
$15,000  as an expense in the three months ended February 29,  2004
and prepaid payroll for the unearned portion of $10,000.

On  June 10, 2003, the Company entered into an agreement with  Erin
Rahe.   The  agreement has a term of one year and may  be  extended
upon  agreement  by  both parties.  Either  party  may  cancel  the
agreement with five days written notice in the event of a  material
violation  of the agreement.  Either party may cancel the agreement
for  any  reason upon 30 days written notice. The compensation  for
the  agreement  was paid with the issuance of 1,000,000  shares  of
common stock.  As of November 30, 2003, the Company had recorded  a
prepaid expense of $12,000.

Note 4 - Notes payable

During  the  three months ended February 29, 2004, an  officer  and
director  loaned  the  Company  $3,500  to  pay  for  general   and
administrative  expenses.  The loan bears no interest  and  is  due
upon demand.  As of February 29, 2004, the amount owed is $3,500.




                                -7-





                        US Biodefense, Inc.
                               Notes

Note 5 - Related party transactions

Office space is provided without charge by an officer, director and
shareholder.  Such costs are immaterial to the financial statements
and,  accordingly, have not been reflected therein.   The  officers
and  directors  of  the  Company are  involved  in  other  business
activities  and  may,  in  the future,  become  involved  in  other
business opportunities.  If a specific business opportunity becomes
available,  such  persons may face a conflict in selecting  between
the  Company  and their other business interests.  The Company  has
not formulated a policy for the resolution of such conflicts.































                                -8-




       Item 2. Management's Discussion and Plan of Operation

Forward-Looking Statements

     This  Quarterly  Report  contains  forward-looking  statements
about  US  Biodefense,  Inc.'s business,  financial  condition  and
prospects  that reflect management's assumptions and beliefs  based
on  information currently available.  We can give no assurance that
the  expectations indicated by such forward-looking statements will
be  realized.  If any of our management's assumptions should  prove
incorrect, or if any of the risks and uncertainties underlying such
expectations should materialize, UBDF's actual results  may  differ
materially from those indicated by the forward-looking statements.

     The  key factors that are not within our control and that  may
have  a  direct bearing on operating results include, but  are  not
limited  to, acceptance of our services, our ability to expand  our
customer base, managements' ability to raise capital in the future,
the retention of key employees and changes in the regulation of our
industry.

     There may be other risks and circumstances that management may
be  unable  to predict.  When used in this Quarterly Report,  words
such    as,     "believes,"    "expects,"   "intends,"     "plans,"
"anticipates,"  "estimates" and similar expressions are intended to
identify forward-looking statements, although there may be  certain
forward-looking statements not accompanied by such expressions.

Plan of Operation

     We  were  incorporated in the State of Utah on June 29,  1983,
under  the  name Teal Eye, Inc.  We merged with Terzon  Corporation
and   changed  our  name  to  Terzon  Corporation  in   1984.    We
subsequently  changed our name to Candy Stripers Candy Corporation.
We  were engaged in the business of manufacturing and selling candy
and  gift items to hospital gift shops across the country.  We were
traded Over-the-Counter Bulletin Board for several years.  In  1986
we  ceased the candy manufacturing operations and filed for Chapter
11  Bankruptcy protection.  After emerging from Bankruptcy in 1993,
we remained dormant until January 1998, when we changed our name to
Piedmont,  Inc.   On  May 13, 2003, we filed an  amendment  to  our
Articles of Incorporation to change our name from Piedmont, Inc. to
US  Biodefense, Inc.  We have not generated any revenues  since  we
emerged from bankruptcy.

     We  intend  to provide diversified professional and  technical
services  involving the application of scientific, engineering  and
management  expertise to provide biological defense  solutions  for
government and commercial customers in the U.S. and abroad.  We are
currently   developing  our  internal  operations  and  researching
potential opportunities for our business.  We expect to continue to
experience  additional expenditures and incur ongoing losses  until
we  are  able  to implement our services and generate revenues  and
cash flows to satisfy our financial obligations.

     We  have  no  cash  on  hand, and may be  unable  to  continue
operations  for  the next at least 12 months if we  are  unable  to
generate revenues or obtain capital infusions by issuing equity  or
debt  securities in exchange for cash.  If we are unable to  obtain
capital  through  issuances  of  equity  or  debt,  David  Chin,  a
shareholder  and President of our company, has verbally  agreed  to
loan  us cash, which shall bear no interest and be due upon demand.
We  have no formal written agreement with Mr. Chin for such  loans,
and  we  cannot guarantee you that we will be able to enforce  this
agreement.  Notwithstanding this, there can be no assurance that we
will  be  able to secure additional funds in the future to stay  in
business.   Our  principal accountants have  expressed  substantial
doubt  about our ability to continue as a going concern because  we
have  limited  operations and have not commenced planned  principal
operations.

     We  currently  do not own any significant plant  or  equipment
that we would seek to sell in the near future.

     Our management does not anticipate the need to hire additional
full-  or  part-  time employees over the next 12  months,  as  the
services  provided by our officers and directors appear  sufficient
at  this time.  We believe that our operations are currently  on  a
small  scale that is manageable by a few individuals.  We outsource
for  the  manufacture of our products, as well as the  hosting  and
maintenance of our web site, thus our responsibilities are  related
predominantly   to   graphic  design  and  administrative   duties.
Additionally,  our  marketing and advertising  efforts  are  mainly
conducted  via  the Internet, and can be designed  by  our  current
staff  or our third-party Internet services firm.  While we believe
that





                                -9-





the  addition of employees is not required over the next 12 months,
we  intend to contract sales representatives to market our products
for  us  on an independent contractor basis.  These representatives
are not intended to be employees of our company.

     We  have  not  paid  for  expenses on behalf  of  any  of  our
directors.   Additionally,  we believe that  this  fact  shall  not
materially change.

                  Item 3. Controls and Procedures

     Within 90 days prior to the date of filing of this report,  we
carried  out  an  evaluation, under the supervision  and  with  the
participation  of  our management, including  the  Chief  Executive
Officer  and  our  Chief  Financial  Officer,  of  the  design  and
operation of our disclosure controls and procedures.  Based on this
evaluation, our Chief Executive Officer and Chief Financial Officer
have  concluded  that our disclosure controls  and  procedures  are
effective  for gathering, analyzing and disclosing the  information
we  are  required  to disclose in the reports  we  file  under  the
Securities Exchange Act of 1934, within the time periods  specified
in  the  SEC's  rules  and forms.  There have been  no  significant
changes  in  our internal controls or in other factors  that  could
significantly affect internal controls subsequent to  the  date  of
this evaluation.


                    PART II - OTHER INFORMATION

                         Item 6. Exhibits

Exhibi  Name and/or Identification of Exhibit
  t
Number

  3     Articles of Incorporation & By-Laws
           a.  Articles of Incorporation of Teal Eyes, Inc.
           Incorporated by reference herein filed as Exhibit (a)
           to Form 10SB12G filed on September 1, 2000.
           b.  Amendment to Articles of Incorporation of Teal
           Eyes, Inc.  Incorporated by reference herein filed as
           Exhibit (b) to Form 10SB12G filed on September 1,
           2000.
           c.  Amendment to Articles of Incorporation of Terzon
           Corporation.  Incorporated by reference herein filed
           as Exhibit (c) to Form 10SB12G filed on September 1,
           2000.
           d.  Amended and Restated Articles of Incorporation of
           Candy Stripers Candy Corp.  Incorporated by reference
           herein filed as Exhibit (d) to Form 10SB12G filed on
           September 1, 2000.
           e.  By-Laws of the Company.  Incorporated by reference
           herein filed as Exhibit (e) to Form 10SB12G filed on
           September 1, 2000.
           f.  Certificate of Amendment to Articles of
           Incorporation filed May 13, 2003.  Incorporated by
           reference herein filed as Exhibit 3 to Form 10-QSB
           filed on July 15, 2003.

  31    Rule 13a-14(a)/15d-14(a) Certifications

  32    Certification under Section 906 of the Sarbanes-Oxley Act
        (18 U.S.C. Section 1350)





                               -10-





                            SIGNATURES

Pursuant to the requirements of the Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.

                       US BIODEFENSE, INC.
                       -------------------
                          (Registrant)

By: /s/ David Chin
    ----------------
David Chin, President





























                               -11-